Table 3

Analysis of the effect of infliximab on BMD using different linear regression models

Models

Cofactors

Femoral neck BMD

Lumbar BMD

BMD variation

P

BMD variation

P

1

Infliximab

0.027

0.001

0.030

0.001

2

Infliximab

0.027

0.001

0.031

0.001

Male sex

-0.009

0.40

0.008

0.47

Age

0.002

0.56

0.005

0.09

3

Infliximab

0.020

0.03

0.033

0.001

Male sex

-0.014

0.22

0.006

0.64

Age

0.001

0.86

0.005

0.15

Patients on steroids

-0.012

0.20

-0.001

0.92

4

Infliximab

0.023

0.01

0.034

0.001

Male

-0.014

0.22

0.006

0.61

Age

-0.001

0.90

-0.001

0.88

Menopause

0.005

0.75

0.022

0.20

Patients on steroids

-0.010

0.29

-0.002

0.87

DAS28

-0.008

0.04

-0.006

0.17

5

Infliximab

0.023

0.02

0.035

0.001

Male

-0.015

0.20

0.007

0.58

Age

-0.001

0.85

0.000

0.95

Menopause

0.006

0.70

0.020

0.25

Patients on steroids

-0.009

0.37

-0.004

0.65

DAS28

-0.008

0.05

-0.006

0.15

Patients on biphosphonates

-0.012

0.29

0.022

0.07

6

Infliximab

0.028

0.002

0.041

0.001

Male

-0.007

0.53

0.010

0.39

Age

-0.002

0.61

0.002

0.63

Patients on steroids

-0.008

0.35

-0.001

0.91

DAS28

-0.007

0.06

-0.007

0.10

Baseline BMD values

-0.042

0.16

-0.080

0.01

All 189 patients were included in several analysis of covariance models for bone mineral density (BMD) variations (final values minus initial values) to analyze the effect of cofactors (continuous variables and discrete variables) on that of infliximab. DAS, Disease Activity Score.

Marotte et al. Arthritis Research & Therapy 2007 9:R61   doi:10.1186/ar2219